C25Fulvestrant (FUL) as first-line therapy in HR+ve,...

Annals of Oncology 2017 / 10 Vol. 28; Iss. suppl_6

C25Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study

Pronzato, P, Mustacchi, G, Riccardi, F, Turletti, A, Michelotti, A, Natoli, C, Livi, L, Del Mastro, L, Donadio, M, Garrone, O, Giordano, M, De Laurentiis, M, Marchetti, P, Montemurro, F, Romagnoli, E,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
28
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx424.024
Date:
October, 2017
File:
PDF, 49 KB
english, 2017
Conversion to is in progress
Conversion to is failed